Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe.
Plaque-busting antibodies reset the time course of amyloid accumulation, but so far provide only hints of a clinical benefit in mild AD. Good news: once gone, plaque stays gone for a while.
ALL NEWS
5781 RESULTS
Sort By:
- Most Recent
- Most Commented
Astroglial Markers Poised for Stardom?
A new PET tracer. Plasma glial fibrillary acidic protein. Two new, promising surrogates for astrogliosis are filling in the Alzheimer’s biomarker toolbox. Both reflect Aβ amyloid better than they do tau tangles.
Shuttle Unloads More Gantenerumab Into the Brain
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.
New Guidelines Proposed for Alzheimer's Disease Postmortem Diagnosis
An international group of researchers* have agreed upon recommendations to revise the criteria for postmortem diagnosis of Alzheimer’s disease (AD)...
Clinicians from Developing Nations Discuss Dementia in Their Populations
As life expectancy increases in countries such as Nigeria, Brazil, China, and others, so does the number of people with dementia. How to provide modern care for them?
Umibecestat-Driven Cognitive Decline Is Reversible
Subtle memory deficits resolved after volunteers stopped taking the Novartis BACE inhibitor.
FTD Fluid Markers for Degeneration: Check. For Pathology: Not Yet.
As FTD consortia chase biomarkers, they see plasma NfL and neuronal pentraxin-2—which reflect neurodegeneration—change before symptoms. Trials nudge progranulin and poly-DP. Still needed: more markers of the pathophysiology that unfolds in the brain.
International Conference on Alzheimer's and Parkinson's Diseases 2021 (Virtual Meeting)
Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit Astroglial Markers Poised for Stardom? Shuttle Unloads More Gantenerumab Into the Brain N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore Where to Now, Phospho-Tau? Clinicians from ...
Michael J. Fox Foundation Launches Big PD Biomarker Study
A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the Parkinson's Progression Markers Initiative (PPMI) ...
COVID-19 Worsens Neurological Problems, Delirium
At AD/PD 2021, clinicians discussed neurological symptoms and brain tissue damage in older people who died from COVID-19.
Guidelines Bring Needed Change, Though Not Enough for Some
U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage. ...
Modern Microscopy
Modern Microscopy Skims Surface of Living Minds and Spines Modern Microscopy Plumbs the Depths of Brain Tissue ...
The Mega-Appeal of Nanomedicine
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD ...
More Needed Than Ever, Brain Banks Are Modernizing But Face Funding Crunch
Banked brain tissue enables crucial advances in the understanding and treatment of degenerative disorders. As appreciation of the many different variants of neurodegenerative disease is growing, well-preserved tissue is in more demand than ever. Are the ...
Stress and Alzheimer’s Disease
With the holidays upon us, are your nerves fraying under the combined pressures of work deadlines, shopping, decorating, and entertaining? Now may be a good time to sit back and consider the effects of stress on the brain. Stress per se is not a cause of ...
Current Filters
- Date Range : All x